Functionality of Albumin in the Context of Hemodialysis
Recruiting
N/A
Interventional Study
Albumin
Dialysis
Redox State
Uremic; Toxemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Universität Duisburg-Essen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin.
The aim of this study is to inves…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen
Exclusion Criteria:
* Age ≤ 18 years
* Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week
* Acute or chronic l…
Contacts